Mutual of America Capital Management LLC Sells 19,063 Shares of STAAR Surgical (NASDAQ:STAA)

Mutual of America Capital Management LLC reduced its position in STAAR Surgical (NASDAQ:STAA - Free Report) by 72.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,396 shares of the medical instruments supplier's stock after selling 19,063 shares during the period. Mutual of America Capital Management LLC's holdings in STAAR Surgical were worth $275,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Arcadia Investment Management Corp MI bought a new stake in STAAR Surgical in the third quarter worth $37,000. Canada Pension Plan Investment Board acquired a new position in shares of STAAR Surgical during the 2nd quarter valued at about $129,000. Van ECK Associates Corp raised its stake in shares of STAAR Surgical by 12.7% in the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier's stock valued at $129,000 after acquiring an additional 393 shares in the last quarter. Larson Financial Group LLC acquired a new stake in STAAR Surgical in the 2nd quarter worth approximately $130,000. Finally, nVerses Capital LLC lifted its holdings in STAAR Surgical by 78.3% in the 3rd quarter. nVerses Capital LLC now owns 4,100 shares of the medical instruments supplier's stock worth $152,000 after purchasing an additional 1,800 shares during the last quarter. 96.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on STAA shares. Stifel Nicolaus dropped their price target on shares of STAAR Surgical from $50.00 to $44.00 and set a "buy" rating on the stock in a research report on Monday, August 26th. Needham & Company LLC reiterated a "hold" rating on shares of STAAR Surgical in a research note on Thursday, October 31st. Finally, Canaccord Genuity Group cut their target price on shares of STAAR Surgical from $41.00 to $31.00 and set a "hold" rating for the company in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $43.33.

STAAR Surgical Trading Up 3.3 %

NASDAQ:STAA traded up $0.92 during trading hours on Friday, hitting $29.10. 269,988 shares of the company traded hands, compared to its average volume of 707,509. STAAR Surgical has a twelve month low of $25.88 and a twelve month high of $52.68. The firm has a 50-day moving average of $30.61 and a 200 day moving average of $36.26. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of 64.05 and a beta of 0.61.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.